Original Research Article

Outcomes of multi drug resistant tuberculosis under programmatic conditions: the experience

Gayatri Devi Yellapu¹, Preethi Koyyana¹*, Vasundhara Nammi², Priyanka Dharshini Dondapati¹, Priyanka Boppe¹

¹Department of Pulmonary Medicine, Andhra Medical College, Visakhapatnam, Andhra Pradesh, India
²District Tuberculosis Officer, Visakhapatnam, Andhra Pradesh, India

Received: 30 January 2020
Revised: 07 February 2020
Accepted: 28 February 2020

*Correspondence:
Dr. Preethi Koyyana,
E-mail: drpreethikoyyana@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Tuberculosis is the most common cause of death from an infectious disease worldwide after HIV/AIDS. Drug resistant tuberculosis continues to be a public health crisis. India stands, one among 27 “high burden” MDR countries and has over 2 million new TB cases every year and TB kills nearly 1000 people every day. The WHO 2018 Global Tuberculosis Report estimated that, worldwide, approximately 3.5 percent of all new TB cases and 18 percent of previously treated cases are caused by MDR or rifampicin mono resistant strains.

Methods: Presumptive drug resistance TB cases were subjected for CBNAAT or LPA to detect resistance patterns. About 231 cases of MDR/RR TB cases after pre-treatment evaluation started on CAT-IV regimen and both interim and final outcomes were analyzed.

Results: Out of 231 cases 172(74.4%) were males and 59(25.6%) were females with age between 13-75yrs. Total of 194 cases culture conversion occurred out of which 28 cases the cultures were reverted back to positives. Final Outcomes were, cured in 84 (36.3%) cases, treatment completed in 42 (18.18%) cases, defaulters in 31 (13.4%) cases, turned to be XDR in 10 (4.32%) cases, treatment failure in 10 (4.32%) cases, 50 (21.6%) cases died, 3(1.29%) cases were transferred out.

Conclusions: Approximately 2/3rd of MDR/RR TB cases are retreatment sputum positive cases. Successful outcome observed in 54.54% of cases only. High rates of deaths and defaulters alarm the necessity of more effective implementation and surveillance of the programme.

Keywords: Multi drug resistant tuberculosis, Outcomes, Pulmonary tuberculosis, Resistance patterns standardized regimen

INTRODUCTION

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide. Tuberculosis is the most common cause of death from an infectious disease worldwide after HIV/AIDS. A major hurdle to TB control is the emergence of mycobacterium resistance to anti-tuberculosis chemotherapy.¹ Drug resistant tuberculosis continues to be a public health crisis. The best estimate is that, worldwide in 2017, 5,58,000 people developed TB that was resistant to rifampicin (RR-TB), the most effective first line drug, and of these 82% had multidrug resistant TB (MDR-TB).¹ Multidrug-resistant tuberculosis (MDR-TB) is defined as resistance to isoniazid and rifampicin.² India stands, one among the 27 “high burden” MDR countries and has over 2 million new TB cases every year and TB kills nearly 1000 people every day. WHO currently estimates that India has about100,000 people with MDR-TB.³
The WHO 2018 Global Tuberculosis Report estimated that, worldwide, approximately 3.5 percent of all new TB cases and 18 percent of previously treated cases are caused by MDR or rifampicin-mono resistant strains. INDIA ranks 1st in having MDR-TB cases, approximately 24%, with an incidence of 1.35,000 i.e. 10/1,00,000 population. Among them 2.8% are new cases and 12% are previously treated cases. The standard treatment for MDR-TB is a 24-month regimen largely comprising second-line drugs that are less effective, more costly and associated with more number of adverse events.

India’s RNTCP under PMDT activities provides a standardized regimen of treatment labeled as CAT IV under DOTS–plus program and it has shown an effectiveness of 61% successful outcomes in MDR TB in resource limited countries. The above data reflects the immense TB burden in INDIA and the need of urgent interventions to bring it down. In this scenario the current study was undertaken to assess different outcomes in MDR-TB patients in the region of Visakhapatnam to highlight both its success and failure under programmatic conditions, and also to see the resistance patterns.

**Objectives**

- To study the outcomes in multi drug resistance tuberculosis patients with standardized regimen under programmatic conditions.
- To observe the different resistance patterns among presumptive pulmonary tuberculosis patients.

**METHODS**

It is a prospective observational study conducted at DOTS plus center, department of pulmonary medicine, GHCCD, Visakhapatnam. All the Presumptive MDR-TB patients who attended the OPD between January 2014 to March 2016 at the above-mentioned DOTS plus site were taken into the study.

**Inclusion criteria**

- All Presumptive DR-TB cases who were resistant to isoniazid and rifampicin(MDR-TB) or Rifampicin (RR-TB).
- Age above 18 years.

**Exclusion criteria**

- Age less than 18 years
- Pregnant women
- XDR-TB
- Not willing to give consent.

Presumptive DR-TB was referred to the following patients in order of their risk i.e. TB patients found positive on any follow-up sputum smear examination during treatment with first line drugs including treatment failures; TB patients who are contacts of DR-TB; previously treated TB patients; new TB patients with HIV co-infection. Pediatric TB non-responders were not included in the study.

A total of 231 patients were enrolled in the study after a written informed consent. Information on demographic and clinical profile of patients including co-morbidities like HIV status, diabetes, smoking habits, and alcoholism were noted. History of previous anti-tuberculosis treatment (ATT) was noted and analyzed. The diagnosis of MDR-TB was done at RNTCP accredited Intermediate Reference laboratory in this hospital, using CBNAAT, line probe assay and liquid culture wherever needed. Different resistant patterns among the presumptive MDR-TB cohort group were noted.

Prior to initiation of treatment, patients were admitted at DOTS PLUS site and pre-treatment evaluation was done after which they were started on standardized regimen (CAT- IV) as per PMDT guidelines. All the patients in the cohort group were followed till the end of the treatment. The last case enrolled was in March 2016, which completed the treatment by March 2018. All the adverse events during the treatment were noted, and necessary interventions had been taken. The status of mycobacterial cultures is generally used to guide, therapy for patients treated in resource-limited settings and is considered to be the most important interim indicator for the efficacy of multidrug-resistant TB treatment.

MDR - TB, cure, treatment completed, death, treatment failure, and treatment defaulter were defined as per the RNTCP guidelines. Successful outcome: Cure and completion of treatment were considered to represent successful outcome.

Non-successful outcome: Defaults, death, change to category V treatment i.e. XDR TB, failure and still on treatment were considered to represent non-successful outcomes.

**Statistical analysis**

Both interim and final outcomes of Cat IV treatment as described by the programme were noted and analyzed. Quantitative variables were summarized as MEAN±SD and qualitative variables as percentage using MS EXCEL.

**RESULTS**

Out of 231 cases 172(74.4%) were males and 59(25.6%) were females with age ranging between 13-75yrs with an average of 36.4±13.5 yrs. Seventeen cases (7.3%) were HIV positive. (Table 1). Among 231 cases sputum positive retreatment cases were 160(69.2%), sputum negative retreatment cases were 13(5.6%), follow up smear positive cases were 39(16.88%), HIV TB co-
infection cases 17(7.3%) and 2(0.86%) cases were contacts of MDR-TB. (Figure 1) Rifampicin resistance was observed in 109 (47.18%) cases, both INH and Rifampicin resistance was observed in 122 (52.8%) cases and additional Ethambutol resistance was observed in 6 cases (Figure 2).

Table 1: Demographic data (n=231).

| Parameter          | Value |
|--------------------|-------|
| Age                | 13-75 |
| Males              | 172 (74.4%) |
| Females            | 59 (25.6%) |
| HIV positive       | 17/231 (7.3%) |

The final outcomes noted were as follows, cured in 84 (36.3%) cases, treatment completed in 42 (18.18%) cases, defaulters in 31 (13.4%) cases, turned to be XDR in 10 (4.32%) cases, treatment failure in 10 (4.32%) cases, 50 (21.6%) cases died and 3(1.29%) cases were transferred out (Figure 3).

DISCUSSION

The emergence of MDR-TB is a global problem, which is threatening to destabilize the best efforts of TB control. To manage MDR-TB in poor economically and resource limited settings, WHO launched the DOTS Plus initiative to develop a global policy to provide technical assistance to DOTS programs and to enable access to second-line drugs under rational use. As the MDR patients are resistant to most of the first line drugs and require judicious and optimal combinations of second line drugs, National programs in resource-poor endemic countries may feel pressured into instituting DOTS-Plus programs for their MDR-TB patients.

The demographic profile of MDR-TB patients in this study was similar to that of studies done by Sangita et al (2010), Sachin S Dole et al (2016), and Deepak et al (2017). Majority of the patients were in the economically productive age group (20-40 years). In this study, there were few patients with HIV infection and these patients had worse outcomes than those who were HIV-negative. Adverse drug reactions were documented in nearly a quarter of the study population with gastrointestinal, psychiatric, and ototoxic reactions being
Majority of the cases (69.2%) were sputum positive retreatment cases which was in agreement with most of the other Indian studies and systematic reviews.\textsuperscript{17-19} Sputum culture conversion at 3\textsuperscript{rd} month occurred in 56.7% of cases, which was low compared to other studies by Sachin S Dole et al and Deepak et al.\textsuperscript{12,13} But sputum culture conversion at end of 6 months was 83.9%, which was in agreement with other recent Indian studies, systematic reviews, and Meta-analysis.

In this study successful outcome was observed in 54.54% which was similar to a study done by Sachin S Dole et al, Sangita V. Patel et al study had a very low successful outcome (38.62%), and in a study by Deepak et al and in a systematic review of 36 studies the successful outcomes were 63% and 62% respectively.\textsuperscript{11,13,18} In this study 21.6% of cases died which was in contrast to other studies ranging from 11% to 16.4%. High death rate might be because of comorbidities and bilateral extensive i.e. far advanced disease at presentation leading to respiratory failure. The only limitation of the study was that it was a single center observational study and factors which because poor outcomes were not analyzed.

**CONCLUSION**

Approximately 2/3rd of MDR/RR TB cases were retreatment sputum positive cases. Successful outcome was observed in 54.54% of cases only. High mortality rate and increased number of defaulters alarms the necessity of more effective implementation and surveillance of the programme. Measures for improving nutritional status and interventions to increase the adherence to treatments might definitely improve the treatment outcomes.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. World Health Organization, Global Tuberculosis Report 2018. Available at: http://www.who.int/tb/publications/global_report/en/. Accessed 01 October 2018.

2. World Health Organization, iris institutional repository for information sharing: Tuberculosis control in the South- East Asia Region ;annual report 2015. Available at: https://apps.who.int/iris/handle/10665/154550. Accessed 11 November 2018.

3. World Health Organization, Multidrug and Extensively Drug-resistant TB (M/XDR-TB) 2010 Global Report on Surveillance and Response. WHO Global Report; 2010. Available at: http://www.who.int/iris/bitstream/10665/44286/1/9789241599191_eng.pdf. Accessed 05 October 2018.

4. Ministry of health & family welfare: central tuberculosis division: government of India. India tb report 2018. Available at: https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=4160&lid=2807. Accessed December 2016.

5. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho ACC et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014 Jul;44(1): 23-63.

6. Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, et al. DOTS-Plus for Patients with Multidrug-resistant Tuberculosis in India: Early Results After Three Years. Ind J Chest Diseases and Allied Sci. 2007;49:75-80.

7. Dhingra VK, Rajpal S, Mittal A, Hanif M. Outcome of multidrug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc. 2008 Jan;55(1):15-21.

8. Monitoring and outcome definitions. In: Guidelines on programmatic management of drug resistant tuberculosis in India 2017. Chapter 8:88-90.

9. Drobniowski F, Eltringham I, Graham C, Magee JJ, Smith EG, Watt B. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax. 2002 Sep 1;57(9):810-6.

10. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis: introducing ‘DOTS plus. Br Med J. 1998;317:671-4.

11. Patel SV, Nimavat KB, Alpesh PB, Shukla LK, Shringarpurea KS, Mehta KG, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (mdr tb) in western India: A prospective study. J Infection and Public Health. 2016;9:478-84.

12. Dole SS, Waghmare VN, Shaikh AM. Clinical Profile and Treatment Outcome of Drug Resistant Tuberculosis Patients of Western Maharashtra, India. J the association of Physicians of India. 2017;65:18-21.

13. Janmeja AK, Aggarwal D, Dhillon R. Analysis of treatment outcome in multi-drug resistant tuberculosis patients treated under programmatic conditions. Int J Res Med Sci. 2017Jun;5(6):2401-5.

14. Törün T, Güngör G, Ozmen I, Bölbükbaşı Y, Maden E, Biçakçı B, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005 Dec;9(12):1373-7.

15. Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004, Int J Tuberc Lung Dis. 2010; 14:275-81.
16. Hoa NB, Nhung NV, Khanh PH, Hai NV, Quyen BT. Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham NgocThach hospital, Ho Chi Minh City, Vietnam. BMC Res Notes. 2015;8:809.

17. Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty 2017 Dec 1;6(1):7.

18. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009 Sep 9;4(9):e6914.

19. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009; 9:153-61.

Cite this article as: Yellapu GD, Koyyana P, Nammi V, Dondapati PD, Boppe P. Outcomes of multi drug resistant tuberculosis under programmatic conditions: our experience. Int J Res Med Sci 2020;8:1475-9.